Share
Howard Hechler
Lumicell, Inc., a company specializing in fluorescence-guided imaging technologies for cancer detection during surgery, has appointed Howard Hechler as Chief Executive Officer. Hechler, who previously served as Senior Vice President of Corporate Development & Strategy and later as President, brings a strong background in investment banking, management consulting, and partnering/M&A roles at companies like Medtronic, Smith & Nephew, and Mallinckrodt Pharmaceuticals.
Hechler is committed to driving market adoption of Lumicell’s FDA-approved imaging platform, aiming to expand its use across solid tumor cancers. He is focused on advancing the company’s mission to improve cancer surgery outcomes and provide hope to patients worldwide.
Lumicell’s Board of Directors expressed strong confidence in Hechler’s leadership, particularly his ability to inspire significant investment and unite surgical oncology around the company's innovative imaging technology. With over 17 million people diagnosed with solid tumors annually, Hechler’s leadership is seen as key to improving surgical precision and patient outcomes.
